Introduction and Aims: Vascular endothelial growth factor (VEGF) promotes endothelial cell proliferation and differentiation and mediates endothelium dependent vasodilatation. Increased serum levels of VEGF have been reported in patients with acute coronary syndromes and gene transfer therapies habe been attemted in patients with coronary artery disease (CAD). We evaluated the impact of VEGF levels on the development of CAD in patients with end-stage renal disease.
Methods:
We studied n=105 patients on chronic dialysis with angiographically confirmed (n=45) or excluded (n=60) CAD, followed up for 3.5 ± 3.1 years after initiation of dialysis. VEGF serum levels at the time of coronany angiography were determined by ELISA. Results: A large variation in VEGF levels was noted among the dialysis patients (mean 440.1 ± 314 pg/dl, median 362.9 pg/dl, range 78.5-1672.0 pg/dl). A weak negativ association of VEGF levels with the time elapsed since the inatiation of dialysis was observed (r=-0.194, p=0.062). VEGF levels were not associated with the sex or the age of the patients, the presence of diabetes mellitus, secondary hyperthyroidism, smoking, treatment with statins, or CRP levels. VEGF levels did not differ significantly between patients with angiographically confirmed (428,4 ± 300) or excluded CAD (449,9 ± 327 pg/dl, ns). There was also no correlation between VEGF levels and the number of affected coronary artery vesels (one vesel CAD: 408, 8 ± 259, two vesel CAD: 361, 8 ± 291, three vesel CAD: 525, 2 ± 379 pg/dl, ns) . Furthermore, VEGF levels were similar among patients who expierenced myocardial infarction or underwend revascularization during follow up (447,5 ± 313) and the rest of the cohort (437,9 ± 317 pg/dl, ns). Conclusions: According to our results, VEGF levels are not associated with the demelopment of coronary artery disease in chronic dialysis patients.
